We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+65.49%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$2.65B
AUM Growth
+$969M
Cap. Flow
+$186M
Cap. Flow %
7.03%
Top 10 Hldgs %
54.64%
Holding
73
New
13
Increased
31
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$49.6M
2
WVE icon
Wave Life Sciences
WVE
+$41.8M
3
QTTB icon
Q32 Bio
QTTB
+$30.2M
4
KRRO icon
Korro Bio
KRRO
+$20.3M
5
RLMD icon
Relmada Therapeutics
RLMD
+$20.2M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$37.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$12.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12M
4
QDEL icon
QuidelOrtho
QDEL
+$10.8M
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 94.97%
2 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
26
Arvinas
ARVN
$541M
$27.5M 1.04%
670,295
-139,328
-17% -$4.08M
TBIO
27
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$26.9M 1.02%
3,304,808
+156,180
+5% +$1.44M
RLMD icon
28
Relmada Therapeutics
RLMD
$570M
$25.9M 0.98%
+664,484
New +$20.2M
AVDL
29
DELISTED
Avadel Pharmaceuticals
AVDL
$25.7M 0.97%
+3,401,434
New +$18M
KRRO icon
30
Korro Bio
KRRO
$165M
$21.8M 0.82%
+26,057
New +$20.3M
CSTL icon
31
Castle Biosciences
CSTL
$960M
$21.7M 0.82%
631,072
-113,973
-15% -$2.79M
MDXG icon
32
MiMedx Group
MDXG
$618M
$20.5M 0.77%
2,702,539
-261,461
-9% -$1.98M
XGN icon
33
Exagen
XGN
$161M
$18.3M 0.69%
718,946
+207,313
+41% +$3.69M
PTGX icon
34
Protagonist Therapeutics
PTGX
$8.83B
$17.3M 0.65%
2,459,988
+1,697,705
+223% +$16.9M
JNJ icon
35
Johnson & Johnson
JNJ
$620B
$17M 0.64%
116,858
– –
NSTG
36
DELISTED
NanoString Technologies, Inc.
NSTG
$16.1M 0.61%
+578,932
New +$14.1M
ABUS icon
37
Arbutus Biopharma
ABUS
$923M
$15.8M 0.59%
5,666,754
+103,787
+2% +$168K
TELA icon
38
TELA Bio
TELA
$42.4M
$14.8M 0.56%
+1,139,358
New +$13.9M
WVE icon
39
Wave Life Sciences
WVE
$1.16B
$13.7M 0.52%
+1,705,474
New +$41.8M
NTRA icon
40
Natera
NTRA
$39.8B
$13.6M 0.51%
402,953
+115,483
+40% +$4.26M
A icon
41
Agilent Technologies
A
$39.7B
$12.8M 0.48%
+149,690
New +$11.8M
RGNX icon
42
Regenxbio
RGNX
$684M
$12.5M 0.47%
305,611
+14,443
+5% +$571K
PODD icon
43
Insulet
PODD
$9.42B
$11.6M 0.44%
67,725
-43,507
-39% -$7.25M
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$11.6M 0.44%
356,752
+16,860
+5% +$523K
QURE icon
45
uniQure
QURE
$3.03B
$10.9M 0.41%
152,096
+7,187
+5% +$395K
CLSD
46
DELISTED
Clearside Biomedical
CLSD
$10.9M 0.41%
250,007
+160
+0.1% +$3.36K
STAA icon
47
STAAR Surgical
STAA
$1.17B
$10.6M 0.4%
+302,211
New +$9.97M
INMD icon
48
InMode
INMD
$870M
$9.8M 0.37%
500,000
– –
TMDX icon
49
Transmedics
TMDX
$2.51B
$9.57M 0.36%
503,266
– –
BWAY
50
Brainsway
BWAY
$608M
$9.35M 0.35%
1,916,852
+247,478
+15% +$1.16M
1
2
3

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q4 2019 Portfolio in Review

As of Q4 2019, RTW Investments held 73 positions worth $2.65B, up 58% from $1.68B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RTW Investments deployed $186M of net new capital in Q4 2019, opening 13 new positions and adding to 31 existing holdings. Its largest new stake was Immunovant: 4,426,106 shares worth $66M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $37.9M trimmed.

  • RTW Investments's largest Q4 2019 buy was Immunovant: 4,426,106 shares worth $66M.
  • RTW Investments added most to Q32 Bio in Q4 2019, an estimated $30.2M increase.
  • RTW Investments's biggest Q4 2019 reduction was Achillion Pharmaceuticals, cutting an estimated $37.9M.
  • RTW Investments fully exited QuidelOrtho in Q4 2019, selling an estimated $10.8M.
  • RTW Investments's ten largest holdings make up 55% of its $2.65B portfolio in Q4 2019.
  • RTW Investments opened 13 new positions and closed 12 in Q4 2019.
  • RTW Investments's portfolio value rose 58% quarter-over-quarter to $2.65B.

Based on RTW Investments's 13F filing for Q4 2019, filed 14 Feb 2020.